OHB's €1 Billion IRIS² Win Was Supposed to Change the Story. The Stock Has Other Ideas.

OHB shares slide 32% over the past month even after a near-€1 billion IRIS² satellite deal, as good news keeps getting sold.

When OHB SE signed a contract worth close to €1 billion to build 18 satellite platforms under Europe's IRIS² program, the Bremen-based company briefly looked like the darling of the SDAX. The stock jumped nearly 10% on the news in late August, and for a moment it seemed the order book had finally caught up with the share price.

Three weeks later, the market has moved on. The shares closed Friday at €177.80, essentially flat on the day, but the broader picture tells a harsher story: a 32% decline over the past month and a level roughly three-quarters below the 52-week high of €688.00 set earlier this spring. Even against the 52-week low of €64.00, the stock still sits 178% higher — a spread that captures just how violently OHB has swung between euphoria and exhaustion.

Every Headline, Same Ending

What makes the pattern striking is how consistently good news has been sold. The SES contract, signed roughly three weeks ago, lifted the stock sharply — and since then it has shed about 10%. The follow-on order for the satellite platforms themselves, announced about two weeks back, failed to reverse the slide; the shares are down 2.8% since that disclosure.

The SDAX inclusion, which STOXX fast-tracked in mid-August, offers the clearest illustration. Over the roughly one month since the index move, OHB has lost 31.4%. Even the European Launcher Challenge agreement between ESA and Rocket Factory Augsburg — an OHB-affiliated venture — signed about two weeks ago, has done nothing to change direction. That deal, covering further development of the RFA ONE Block 2 rocket and ground infrastructure through mid-2029, has been followed by a 5.8% decline.

The dynamic extends beyond company-specific news. On September 7, the stock reportedly gained sharply in intraday trading after a German rocket built by Isar Aerospace reached orbit — a company OHB has no direct role in building. The move underscored how readily investors lump the entire European "New Space" narrative together and treat OHB as its most prominent listed proxy.

A Valuation That Ran Ahead of Itself

For all the recent weakness, OHB remains up 166% on the year. That gain is precisely what makes the current retreat look less like a verdict on the business and more like a valuation normalizing after a furious run. The IRIS² contract is substantial and long-dated: the first satellites are slated for readiness in 2029, with service commencing in 2030. Reuters has reported that OHB expects additional orders as part of the broader project. That is a predictable, multi-year pipeline — not the kind of explosive catalyst that justifies doubling a share price in a matter of months.

The sell-the-news mechanics have been on full display. The initial contract announcement produced a sharp rally; by the following day, reports pointed to renewed pressure, with the elevated valuation after the jump cited as the trigger. The Isar effect a week later was another straw fire — a brief lift that left the fundamental order backlog untouched.

Technicals Point to an Oversold Consolidation

On the charts, the stock trades roughly 23% below its 50-day moving average and well under its 200-day average. A Relative Strength Index reading of 33.3 signals oversold conditions, while annualized 30-day volatility of 76% reflects the nervousness running through the order book. Both suggest the selloff has come a long way without yet producing a clear stabilization.

What the shares lack right now is a fundamental anchor for a near-term turn. The next scheduled markers for investors are Berenberg's analyst event on September 21 — where management is expected to address the order situation and margin outlook following the SES deal — and the Q3 2026 earnings release with presentation on November 12. Until then, the stock is likely to take its cues from broader market risk appetite and the afterglow of recent contract announcements, with no fresh corporate news on the horizon.

The November report will be the real test. Only then will it become clear whether the IRIS² award and the wider pipeline are translating into revenue and margin progress — or whether the story so far has been one of valuation and sentiment, driven by sector-wide headlines like the Isar flight, rather than hard numbers. For now, OHB remains a stock that swings between euphoric rallies and sobering corrections, without having settled into a stable valuation range.